Skip to main content
Phoenix Ho, MD, Pediatric Hematology & Oncology, Seattle, WA

PhoenixAHoMD

Pediatric Hematology & Oncology Seattle, WA

Pediatric Hematology & Oncology at Seattle Children's Hospital

Dr. Ho is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ho's full profile

Already have an account?

  • Office

    4800 Sand Point Way NE
    Seattle Children's Hospital
    Seattle, WA 98105
    Phone(206) 987-2106
    Fax(206) 987-3946
  • Is this information wrong?

Education & Training

  • U Washington Affil HospsFellowship, 2009
  • Yale-New Haven Hospital
    Yale-New Haven HospitalResidency, Pediatrics, 2006
  • Yale-New Haven Hospital
    Yale-New Haven HospitalInternship, Pediatrics, 2003 - 2004
  • Northeastern Ohio University College of MedicineClass of 2003

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2006 - 2023
  • American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML  
    Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood

Grant Support

  • Exploiting WT1 Alterations in Pediatric AMLSt. Baldrick's Foundation2012–2014
  • Exploiting WT1 Genomic Alterations for Target Identification and Minimal Residual Disease Monitoring in Pediatric AMLAlex's Lemonade Stand Foundation2012–2013
  • Implications of s-SHIP Expression and SHIP Alterations in AMLNICHD2009–2012
  • SHIP and WT1 Alterations as Markers of PI3K/Akt Activation in Pediatric AMLMary Claire Satterly Foundation2011
  • Implications of s-SHIP Expression and SHIP Alterations in AMLAmerican Society of Clinical Oncology2009–2010